Teaching old drugs new tricks at the Small Molecule Discovery Center: Arthritis drug could treat dysentery

Teaching old drugs new tricks at the Small Molecule Discovery Center: Arthritis drug could treat dysentery

The UCSF School of Pharmacy’s Small Molecule Discovery Center (SMDC) provided a key assist to researchers seeking to repurpose existing drugs to treat the worldwide scourge of amoebic dysentery.

In the June, 2012 issue of Nature Medicine (and online in advance on Nature’s web site), researchers from seven labs including the UCSF Sandler Center for Drug Discovery and the SMDC (which is administered by the Department of Pharmaceutical Chemistry) report that an inexpensive off-patent drug for rheumatoid arthritis, auranofin, is 10 times more potent than the current treatment against a particular amoeba that is a key cause of human dysentery. Such gastrointestinal infections affect up to 50 million people and cause about 70,000 deaths annually, making it the fourth leading cause of mortality from protozoan infections worldwide.

Michelle Arkin, PhD, SMDC associate director for biology and faculty member in the Department of Pharmaceutical Chemistry, and Steven Chen, a specialist at the SMDC, worked with Anjan Debnath, PhD, a UCSF School of Medicine postdoctoral fellow, to develop a high-throughput screen (i.e., fast, simultaneous, automated) of hundreds of potential drug compounds. In particular, they were able to conduct such screening in an oxygen-free (anaerobic) environment that mimicked the natural environment of the disease-causing amoebas. The screening identified auranofin as especially active against the parasite, which was followed by confirmation of its effectiveness in laboratory and animal studies.

Based on their results, the scientists received orphan drug status for auranofin from the U.S. Food and Drug Administration and have applied for approval to start clinical trials testing the parasite treatment in humans.

More:

Lab Tests Show Arthritis Drug Effective Against Global Parasite - UCSF.edu

A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target - Nature Medicine


About the School: The UCSF School of Pharmacy is a premier graduate-level academic organization dedicated to improving health through precise therapeutics. It succeeds through innovative research, by educating PharmD health professional and PhD science students, and by caring for the therapeutics needs of patients while exploring innovative new models of patient care. The School was founded in 1872 as the first pharmacy school west of the Mississippi River. It is an integral part of UC San Francisco, a leading university dedicated to promoting health worldwide.